In-hospital complications and long-term outcomes of the paclitaxel drug-eluting stent in acute ST-elevation myocardial infarction: a real-world experience from a high-volume medical center

Shammas, Nicolas W.; Shammas, Gail A.; Hahn, A; Jerin, Michael; Dippel, Eric J.; Winter, Matthew C

doi:10.1016/j.carrev.2009.01.007

Cited by 6 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to our study, COMPARE included patients with both STEMI and non-STEMI and the prevalence of cardiovascular risk factors was lower than in our population. Prior observations have shown that PES may be associated with MACE rates N10% in patients undergoing primary PCI [15]. In our study, the use of EES yielded MACE rates b10%, while the MACE rate seen with PES was 16%.…”

Section: Discussioncontrasting

confidence: 43%

Safety and efficacy of everolimus-eluting stents compared with first-generation drug-eluting stents in patients undergoing primary percutaneous coronary intervention

Escárcega

Baker

Magalhães

et al. 2014

Cardiovascular Revascularization Medicine

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 43%

Safety and efficacy of everolimus-eluting stents compared with first-generation drug-eluting stents in patients undergoing primary percutaneous coronary intervention

Escárcega

Baker

Magalhães

et al. 2014

Cardiovascular Revascularization Medicine

View full text Add to dashboard Cite

“…The challenges with using DES include: 1) non-selective drug intervention which not only effectively inhibits the proliferation of VSMCs (vascular smooth muscle cells), but also inhibits endothelial proliferation, and the progression of re-endothelialization which can result in a loss of contact inhibition in VSMCs [ 5 ]. Although anticancer drugs have been shown to effectively inhibit VSMC proliferation, this is accompanied by a restenosis rate of 5% -10%, and anticancer drugs such as paclitaxel cause hyperlipidemia with bone marrow suppression and side effects [ 6 , 7 ]. An ideal coating drug should therefore selectively inhibit the proliferation of VSMCs while maintaining the functional integrity of VECs (vascular endothelial cells).…”

Section: Introductionmentioning

confidence: 99%

Targeted Inhibitory Effect of Lenti-SM22alpha-p27-EGFP Recombinant Lentiviral Vectors on Proliferation of Vascular Smooth Muscle Cells without Compromising Re-Endothelialization in a Rat Carotid Artery Balloon Injury Model

et al. 2015

View full text Add to dashboard Cite

AimsIn-stent restenosis remains a serious problem after the implantation of drug-eluting stents, which is attributable to neointima formation and re-endothelialization. Here, we tried to find a new method which aims at selectively inhibiting proliferation of vascular smooth muscle cells (VSMC) proliferation without inhibition of re-endothelialization.Methods and ResultsWe used the smooth muscle-specific SM22alpha promoter in a recombinant lentiviral vector to drive overexpression of cell-cycle inhibitor, p27, in VSMCs. p27 effectively inhibited VSMC proliferation mediated by cell cycle arrest at the G0/G1 checkpoint. The SM22alpha-p27 lentiviral vector inhibited VSMC proliferation more effectively than paclitaxel. Rats infected with Lenti-SM22alpha-p27 had a significantly lower intima/media (I/M) ratio and also showed inhibition of restenosis on day 28 after balloon injury. Moreover, the repair of injured endothelium, and re-endothelialization of the carotid artery wall, was not affected by the smooth muscle cell-specific expression of p27.ConclusionA recombinant lentiviral vector carrying the SM22alpha promoter was used to effectively infect and selectively overexpress p27 protein in VSMCs, leading to inhibition of intimal hyperplasia without compromising endothelial repair.

show abstract

“…8,9) Everolimus-eluting stents (EES; Xience V, Abbott Vascular, Santa Clara, CA, USA and Promus; Boston Scientific, Natick, MA, USA) are a new generation of DES that have demonstrated safety and efficacy compared with first-generation DES in several clinical trials and are widely used in clinical practice. [10][11][12][13] The use of DES is recommended for primary PCI in the setting of ACS in the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.…”

Section: 2)mentioning

confidence: 99%

Mid-Term Clinical Outcomes of ACS and Non-ACS Patients Treated With Everolimus-Eluting Stents

et al. 2012

View full text Add to dashboard Cite

SummaryDrug-eluting stents (DES) have proven to be effective for reducing the rate of restenosis, whereas stent thrombosis (ST) after DES implantation has raised safety concerns. Everolimus-eluting stents (EES) are a new generation of DES that have demonstrated safety and efficacy compared with first-generation DES. However, the use of EES in patients presenting with acute coronary syndrome (ACS) has not been adequately investigated. We compared the clinical outcomes between the ACS and non-ACS groups treated with EES. A total of 335 consecutive patients who received EES implantation between January 2010 and January 2011 were investigated (ACS; n = 172, non-ACS; n = 163). Clinical outcome data were obtained for 94.3% of the patients. Follow-up angiography was performed in 58.5% of all patients. The median follow-up period was 8 months in both groups. Clinical outcomes were not statistically different between the groups. The rate of target lesion revascularization (TLR) was 2.5% in the ACS group and 3.8% in the non-ACS group (P = 0.37). MACE occurred in 8.2% of the ACS group and 10.2% of the non-ACS group (P = 0.54). A definite ST was identified in one patient in each group (P = 0.75). The unadjusted cumulative event rates estimated by the Kaplan-Meier method and the log-rank test showed no significant difference between the groups for TLR, target vessel revascularization (TVR), all-cause death, or MACE. In conclusion, EES was safe and efficacious for patients presenting with ACS, as well as for those with non-ACS during a mid-term follow-up period. (Int Heart J 2012; 53: 215-220) Key words: Everolimus-eluting stents, Acute coronary syndrome, Stent thrombosis P ercutaneous coronary intervention (PCI) is an established strategy in patients with coronary artery diseases, including acute coronary syndrome (ACS) and non-ACS. 1,2)Drug-eluting stents (DES) have proven to be effective for reducing the rate of restenosis in patients receiving PCI, [3][4][5][6][7] while in contrast safety concerns have been raised for late or very late stent thrombosis (ST) after DES implantation. 8,9) Everolimus-eluting stents (EES; Xience V, Abbott Vascular, Santa Clara, CA, USA and Promus; Boston Scientific, Natick, MA, USA) are a new generation of DES that have demonstrated safety and efficacy compared with first-generation DES in several clinical trials and are widely used in clinical practice. [10][11][12][13] The use of DES is recommended for primary PCI in the setting of ACS in the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 1) However, the DES used in the previous clinical trials supporting the guideline were sirolimus-eluting stents (SES) or paclitaxel-eluting stents (PES).14-17) Therefore, whether EES demonstrates safety and efficacy in the setting of ACS is of interest. We studied the clinical outcomes in patients treated with EES, and compared the outcomes between the ACS and non-ACS groups.

show abstract

In-hospital complications and long-term outcomes of the paclitaxel drug-eluting stent in acute ST-elevation myocardial infarction: a real-world experience from a high-volume medical center

Cited by 6 publications

References 22 publications

Safety and efficacy of everolimus-eluting stents compared with first-generation drug-eluting stents in patients undergoing primary percutaneous coronary intervention

Safety and efficacy of everolimus-eluting stents compared with first-generation drug-eluting stents in patients undergoing primary percutaneous coronary intervention

Targeted Inhibitory Effect of Lenti-SM22alpha-p27-EGFP Recombinant Lentiviral Vectors on Proliferation of Vascular Smooth Muscle Cells without Compromising Re-Endothelialization in a Rat Carotid Artery Balloon Injury Model

Mid-Term Clinical Outcomes of ACS and Non-ACS Patients Treated With Everolimus-Eluting Stents

Contact Info

Product

Resources

About